Connect with us

Cannabis News

Bountiful Farms goes best in New England at NECANN Cup

Published

19 minutes ago

on

Bountiful Farms placed first and second in the licensed solvent-free concentrate division at this year’s NECANN Cup, then also won the mixed licensed and unlicensed division to win best overall, putting the Massachusetts operator in the running for best in show with the highest-scoring product in New England.

© Bountiful Farms

NECANN is the largest B2B cannabis event in New England and the second largest in the country, attracting over 9,000 attendees. Everything is unbranded. Licensed and unlicensed operators in the six New England states compete only in product. Zachary Taylor, Director of Agriculture at Bountiful Farms, says the win for Maine’s craft growers means a lot to him and his team. “Whenever you compete against Maine, with its regulations and the craft culture of the caretakers, to be considered a craft on our scale is the greatest honor. When you look at cups across the nation, you see cups of culture, and Maine is always well represented. To be recognized on the same playing field and to excel at this scale is very difficult, and I don’t think that’s what people mean.”

Of course, rosin isn’t given more forcefully to Bountiful Farms. But Zach in a clean way© Bountiful Farms he says, “A good raisin doesn’t appear out of nowhere. It comes from the flower.” The award-winning genetics were bred by Crystal Rose, and built around a high-resin, terpene-rich expression.

“The buds come in within 15 minutes of harvest, it’s like a timer,” Zach says. “Then we move them to a chest freezer, before moving them to an aisle freezer, where they’ll sit until they’re cleaned. All the rosin is pressed by hand in a hydraulic press.” At its scale, Bountiful Farms must use automation to achieve consistently high quality. “But we have very practical components,” he said. “The backlash of the press tells you how hard it is to go. Same approach with agitation, for example. The flower heads themselves, how we maintain the integrity of the trichome, the rise time of the wash, the temperatures: everything is handled like a small-scale race.”

That level of attention comes from the team. Matt Bearup, now a solventless QC manager, started growing and built the hash lab from the ground up all by himself. There are currently eight hash makers, all passionate about complex genetics and terpenes. Strains include not only the main terpenes, but also tasting notes and effects. Using the SC Lab framework, limonene as the current focus. “There’s not a lot of that in the hashish sector in particular. Several growers are moving in that direction.”

© Bountiful Farms

“There’s not a lot like it. Several breeders are moving in that direction.”

Bountiful Farms has been producing rosin since 2021, when the category had little traction© Bountiful Farms in Massachusetts. Since then, the company has expanded into a high-end cultivation center to produce even more rosin. They operate two production rooms and processes not only for themselves, but also for other clients including Native Sun, Breathe Free and u4ea. They have recently opened two new dispensaries, allowing them to expand into recreational retail from 2021. Another limited release of the full melt is planned, along with a dual-cartridge solvent-free pen developed with O2 Vapes, two flavors in one device.

“When you bring award-winning companies together, you get products that represent the industry at its best. Massachusetts deserves its place among the leaders in this industry. When we win, the industry wins.”

For more information:
Prosperous Farms
prosperous farm. take care of

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis News

Federal Drug Testing Rule Will Require ‘Directly Observed’ Urine Collection From Truck Drivers

Published

25 minutes ago

on

May 25, 2026

By

“A month that goes by without an oral fluid test is another month when federal employees with paruresis face anxiety, discrimination, and barriers.”

By Kastalia Medrano, Filter

The Department of Transportation will require “directly observed” urine drug testing in federal employment situations where saliva testing is required but not possible. The clarification of DOT drug and alcohol testing procedures is the latest development in a years-long push by the trucking industry. oral fluid testing as an alternative to urine testing.

The new rule was published in the Federal Register on May 11, and will go into effect on June 10.

Truck drivers, who are subject to a large number of federal regulations, do not choose the method of drug testing, while DOT-regulated employers do. The campaign to implement oral fluid testing has been led by the American Trucking Association (ATA), which believes it is necessary to “keep drivers with disabilities off the road and maintain the trucking industry’s commitment to safety.”

The Substance Abuse and Mental Health Services Administration (SAMHSA) approved lab-based oral fluid testing in 2019, and the DOT finalized its regulations in 2023 allowing employers to choose this as an alternative to urine testing. But the actual implementation requires at least. Two laboratories approved by the Food and Drug Administration to process tests—one for the initial analysis and another to confirm the results. There are currently zero.

Oral fluid testing is attractive to many employers for a number of reasons, one of which is its effectiveness in detecting drug use within hours compared to urine drug testing. While the trucking industry has become the public face of the campaign, the regulations also affect federal workers in the commercial aviation, railroad, public transportation and pipeline sectors.

One of the main concerns expressed by the trucking industry has been that urine drug screens are not visible, making it easier to avoid oral fluid testing. Another concern is paruresis, commonly referred to as “shy bladder” syndrome: if a driver can’t urinate when they need to, they’re stuck for a three-hour wait, which obviously affects their arrival time. And if they still cannot produce urine during this period, they are considered to have refused to take the test and are removed from their duties. To return, they must “pass” a urine test watched by a same-sex observer.

New DOT the rule also updates existing terminology by replacing the word “gender” with the word “sex” in accordance with President Donald Trump’s January 2025 executive order “Defending Women from Gender Ideological Extremism and Restoring Biological Truth to the Federal Government.”

“A month that goes without an oral fluid test is another month when federal employees with paruresis face anxiety, discrimination and professional barriers,” Dr. Steven Soifer, co-founder of the International Paruresis Society, said in March. “We have been working on this issue since our inception (30 years ago). Our members ask the same question every day: When will the federal government finish the work it has already approved?”

In April, at the request of ATA, six members of Congress he wrote Robert F. Kennedy Jr. to the Secretary of the Department of Health and Human Services citing FDA regulatory hurdles as the reason why laboratories in the United States are not certified to process oral fluid tests.

They cited an analysis by Quest Diagnostics that showed a 370 percent increase in “replaced” urine specimens from 2022 to 2023. Quest has its own laboratory-based oral fluid collection method, Quantisal™, and has therefore been an ardent supporter of the campaign.

On May 1, the FDA a notice with the intention of considering revising the requirements for toxicology studies. That same day SAMHSA a the list It confirms that currently certified laboratories, which will probably be updated in the future, but are not available at the moment.

However, at the end of the day, HHS handles oral fluid testing in a similar scenario to hair follicle testing. The department promised to create guidelines for hair testing in 2015, but has yet to do so.

This the article originally posted by The filteran online magazine that deals with drug use, drug policy and human rights from a harm reduction perspective. Follow Filter on Bluesky, X or Facebookand sign up for their newsletter.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

TSA clarifies that cannabis policy has not changed

Published

1 day ago

on

May 24, 2026

By











Over the past week, many news organizations have been running exaggerated headlines about a supposed change by the federal government to allow marijuana to be brought into airports and airplanes. But it’s not true, the Transportation Security Administration (TSA) tells Marijuana Moment.

“TSA’s policy on medical marijuana has not changed,” a TSA spokeswoman said in an email Wednesday.

“According to the TSA website: If any illegal substance or evidence of criminal activity is found during the security screening, TSA will refer the matter to law enforcement,” they said. While it’s true that the agency’s list of medical marijuana “What can I bring?” section of its website was updated on April 27, there were no major changes in policy.

Currently, the website says “Yes,” passengers can carry medical marijuana in carry-on and checked bags with special instructions. But the TSA cannabis policy has said “Yes” to medical marijuana, with the same caveats, since 2019.

Read more at Marijuana Moment










Continue Reading

Cannabis News

Alabama Officials Move To Delay Automatic Rescheduling Of Marijuana Under State Law Following Trump’s Federal Move

Published

1 day ago

on

May 24, 2026

By

“We’re not saying Alabama won’t do this. We’re definitely going to do this, but if you get it without objection, it’s scheduled right away.”

By Anna Barrett, Alabama Reflector

The governing body of the Alabama Department of Public Health voted Thursday against the federal rescheduling of marijuana, saying state health officials needed more time to determine how to implement it.

Dr. Scott Harris, Alabama’s top health official, told members of the state’s Public Health Commission that the state has “full intent” to implement the change.

“We’re not saying Alabama won’t do this,” Harris told the committee. “We’ll certainly do this, but if you get it without objection, it’s scheduled immediately. If you do nothing, it’s scheduled within 30 days. I’m going to ask you to take the third option, which is to oppose it. Then we just have a little time to figure this out with all our other stakeholders.”

The committee’s vote was unanimous. Brian Hale, ADPH’s legal director, said the objection would be open to public comment during the meeting. This period would last 30 to 60 days.

“The objection is simply to allow more time for input on the implications of this rescheduling,” Hale said. “There will be a public hearing, we’ll see the comments that way, and then we’ll talk to other stakeholders, licensing boards and others who might be affected to see what their input might be.”

In April, the US Department of Justice (DOJ) moved marijuana from Schedule I — the Drug Enforcement Administration’s (DEA) list of drugs with the least amount of abuse and legal use — to Schedule III, which, according to the DEA, drugs have a moderate to low potential for physical and psychological dependence. The order followed an executive order President Donald Trump signed in December to keep the DOJ on track to reschedule.

Former President Joe Biden ordered the DOJ to reschedule the drug in 2024, but hearings on the move were canceled in early 2025.

The federal mandate applies to medical marijuana products in states that allow the use of the drug. The move means those businesses can deduct business expenses from federal taxes and investigators have access to legal products in the state. As a Schedule I drug, only cannabis grown in a federal facility could be researched, greatly limiting the supply available to researchers.

Alabama has a medical cannabis program approved by the Legislature in 2021. A Montgomery The dispensary said last week it hopes to make medical marijuana available to patients soon. A message seeking comment from Vince Schillec, the dispensary’s owner, was left Thursday afternoon.

Harris said the reconsideration would not violate state law, but after speaking with the Alabama Medical Cannabis Commission (AMCC), he was unsure how the reconsideration would affect the program.

“We’ve worked very hard to try to figure out what the ramifications of this are. There are a number of things that don’t completely conflict with state laws or other regulations, but they require some thought as to how to implement them,” Harris said.

Justin Aday, AMCC’s general counsel, said in a telephone interview that the commission does not foresee any immediate impact from the federal reorganization or a delay in the reorganization at the state level.

“We certainly understand the commission and the desire to gather additional information about the implications of the federal reorganization and what the implications would be, depending on how medical cannabis is scheduled at the state level,” Aday said. “We will certainly participate in that process as necessary, and we will provide all the information we can.”

This story was first published by the Alabama Reflector.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media